Evaluation of Isolated Elevated RBC Count
Start by checking the serum erythropoietin (EPO) level and obtaining a detailed history for secondary causes—this is the most practical and cost-effective first step after confirming the elevation is real and not due to dehydration or lab error. 1
Initial Assessment
First, confirm this is a true elevation by ensuring:
- The hemoglobin/hematocrit is above the 95th percentile for sex and race-adjusted norms
- There's no clinical dehydration (vomiting, diarrhea, diuretic use, severe burns) causing relative polycythemia 1
- The value represents a documented increase from the patient's baseline 1
Common pitfall: Many "elevated" values simply represent the extreme high-normal range (above 95% but still physiologic). In one study of 248,839 patients, 5.99% of men had Hb >165 g/L but most had no pathology 2. Don't pursue extensive workup for borderline values without additional concerning features.
Diagnostic Algorithm
Step 1: History and Physical Examination
Look specifically for:
- Smoking history (carbon monoxide-induced polycythemia) 1
- Sleep symptoms (sleep apnea/hypoventilation syndromes) 1
- Cardiac or pulmonary disease (hypoxia-driven) 1
- High-altitude residence 1
- Medication use (EPO, androgens) 1
- Symptoms suggesting polycythemia vera: aquagenic pruritus, erythromelalgia, unusual thrombosis, splenomegaly 1
- Tumor history (renal cancer, uterine leiomyoma, pheochromocytoma, meningioma) 1
Step 2: Serum EPO Level
This is your most valuable initial test 1:
- Low EPO (sensitivity ~70%, specificity >90% for PV): Highly suggestive of polycythemia vera—proceed to JAK2 mutation testing 1
- Normal EPO: PV remains possible; consider JAK2 testing if clinical suspicion exists 1
- High EPO: Points toward secondary polycythemia from hypoxia or inappropriate EPO production 1
Key insight: PV is unlikely with elevated EPO, but can present with normal EPO 1. The test helps stratify, not definitively diagnose.
Step 3: JAK2 Mutation Testing
If EPO is low-normal and secondary causes are excluded, test for JAK2 mutations 3, 4. This identifies the clonal myeloproliferative disorder polycythemia vera, which carries thrombotic/hemorrhagic risks and leukemic transformation potential 3.
Step 4: Bone Marrow Examination (If Needed)
Reserve this for equivocal cases where 1:
- EPO is low or normal
- JAK2 is negative but clinical suspicion for PV remains high
- You need to distinguish PV from other myeloproliferative disorders
Characteristic findings include hypercellularity, increased/clustered megakaryocytes, and decreased iron stores 1.
When to Avoid Unnecessary Testing
Do NOT order red cell mass (RCM) measurements in routine practice 1:
- If hematocrit >60% without obvious hemoconcentration, RCM is redundant (almost always elevated)
- Normal RCM doesn't exclude PV (misses left-tail distribution)
- Clinical dehydration doesn't need RCM confirmation
- Modern EPO and JAK2 testing are more practical and cost-effective
Do NOT pursue extensive workup if 1:
- Isolated hematocrit <60% without PV-related features (thrombocytosis, leukocytosis, splenomegaly, microcytosis)
- Simply repeat in 3 months
Secondary Causes to Exclude
Hypoxia-Driven (EPO-mediated):
- Chronic lung disease
- Cardiac right-to-left shunts
- Sleep apnea/hypoventilation
- Smoking (chronic CO exposure)
- High-altitude living
- High oxygen-affinity hemoglobinopathy 1
Hypoxia-Independent:
- Renal artery stenosis
- Tumors producing EPO (renal, hepatic, cerebellar hemangioblastoma)
- Post-renal transplant erythrocytosis
- Congenital polycythemia (EPOR mutations) 1
Clinical Context Matters
In young adults (16-35 years), one study found that among 56 patients with elevated hemoglobin, 43% were obese, 59% were smokers, and hypoxia was the most common secondary cause identified 5. This underscores the importance of addressing modifiable factors before extensive hematologic workup.
Critical point: The diagnostic workup should only be pursued aggressively when hemoglobin/hematocrit is significantly elevated OR when borderline elevations occur with other myeloproliferative features 1. The isolated use of hemoglobin thresholds leads to substantial unnecessary testing 2.